应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
UPB UpStream Bio Inc.
盘前交易 12-16 05:44:30 EST
27.20
+0.06
+0.22%
最高
27.95
最低
26.68
成交量
117.36万
今开
27.56
昨收
27.14
日振幅
4.68%
总市值
14.70亿
流通市值
8.55亿
总股本
5,404万
成交额
3,209万
换手率
3.74%
流通股本
3,142万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Upstream Bio, Inc.2025财年第三财季实现净利润-33.75百万美元,同比减少111.07%
市场透视 · 11-14
Upstream Bio, Inc.2025财年第三财季实现净利润-33.75百万美元,同比减少111.07%
UpStream Bio Inc.:未观察到严重不良事件 安全性表现良好且与前期研究结果一致
美股速递 · 09-02
UpStream Bio Inc.:未观察到严重不良事件 安全性表现良好且与前期研究结果一致
UpStream Bio Inc.公布Verekitug治疗慢性鼻窦炎伴鼻息肉2期临床试验积极顶线结果
美股速递 · 09-02
UpStream Bio Inc.公布Verekitug治疗慢性鼻窦炎伴鼻息肉2期临床试验积极顶线结果
单月超6亿美元,医药企业IPO规模重返疫情前水平
财通社 · 2024-11-25
单月超6亿美元,医药企业IPO规模重返疫情前水平
暂无数据
公司概况
公司名称:
UpStream Bio Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。
发行价格:
--
{"stockData":{"symbol":"UPB","market":"US","secType":"STK","nameCN":"UpStream Bio Inc.","latestPrice":27.2,"timestamp":1765832400000,"preClose":27.14,"halted":0,"volume":1173600,"delay":0,"floatShares":31417476,"shares":54038591,"eps":-2.624147,"marketStatus":"盘前交易","change":0.06,"latestTime":"12-16 05:44:30 EST","open":27.56,"high":27.945,"low":26.675,"amount":32088656.8728,"amplitude":0.046794,"askPrice":39.29,"askSize":100,"bidPrice":20.58,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.624147,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"listingDate":1728619200000,"exchange":"NASDAQ","adjPreClose":27.2,"postHourTrading":{"tag":"盘后","latestPrice":27.2,"preClose":27.2,"latestTime":"19:47 EST","volume":9084,"amount":247133.33,"timestamp":1765846035007},"volumeRatio":2.8512399105003783,"impliedVol":1.2372,"impliedVolPercentile":0.8205},"requestUrl":"/m/hq/s/UPB/tweets","defaultTab":"tweets","newsList":[{"id":"2583529595","title":"Upstream Bio, Inc.2025财年第三财季实现净利润-33.75百万美元,同比减少111.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583529595","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583529595?lang=zh_cn&edition=full","pubTime":"2025-11-14 00:00","pubTimestamp":1763049659,"startTime":"0","endTime":"0","summary":"11月14日,Upstream Bio, Inc.公布财报,公告显示公司2025财年第三财季净利润为-33.75百万美元,同比减少111.07%;其中营业收入为683000.00美元,同比增加12.52%,每股基本收益为-0.63美元。从资产负债表来看,Upstream Bio, Inc.总负债12.61百万美元,其中短期债务716000.00美元,资产负债比为0.32,流动比率为0.33。机构评级:截至2025年11月14日,当前有3家机构对Upstream Bio, Inc.目标价做出预测,其中目标均价为52.33美元,其中最低目标价为35.00美元,最高目标价为75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000227950290a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114000227950290a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["UPB","TSLP","BK4139"],"gpt_icon":1},{"id":"1130035913","title":"UpStream Bio Inc.:未观察到严重不良事件 安全性表现良好且与前期研究结果一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1130035913","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130035913?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:03","pubTimestamp":1756807381,"startTime":"0","endTime":"0","summary":"UpStream Bio Inc.宣布,在研究中未观察到严重不良事件,药物整体耐受性良好,安全性表现与此前的研究结果保持一致。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UPB"],"gpt_icon":0},{"id":"1116725214","title":"UpStream Bio Inc.公布Verekitug治疗慢性鼻窦炎伴鼻息肉2期临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1116725214","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116725214?lang=zh_cn&edition=full","pubTime":"2025-09-02 18:01","pubTimestamp":1756807283,"startTime":"0","endTime":"0","summary":"UpStream Bio Inc.宣布,其针对慢性鼻窦炎伴鼻息肉(CRSwNP)治疗药物Verekitug的2期临床试验Vibrant获得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UPB","BK4139"],"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元,医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来,生物医药领域已经有30家公司IPO上市,累计融资规模超40.49亿美元,其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域,阿斯利康以总价18亿美元收购AmolytPharma,获得了处于临床3期的PTH1R激动剂eneboparatide,目前该疗法已经获得了FDA快速通道认定,另一家药企AscendisPharma的Yorvipath获得FDA批准上市,用于治疗成人慢性甲状旁腺功能减退。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","BDMD","AVTE","MNQmain","PSQ","UPB","BK4007","ASO","BK4139","BK4539","BK4082","OMGA","SQQQ","APGE","SYRS","SEPN","BK4020",".IXIC","NQmain","BK4561","QID","TSLP","GPCR","BK4200","GLYC","QLD","CAMP","TQQQ"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.upstreambio.com","stockEarnings":[{"period":"1week","weight":-0.0611},{"period":"1month","weight":0.1088},{"period":"3month","weight":0.5677},{"period":"6month","weight":1.5564},{"period":"1year","weight":0.3432},{"period":"ytd","weight":0.6545}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Upstream Bio, Inc.于2021年4月在特拉华州注册成立。他们是一家临床阶段的生物技术公司,开发炎症性疾病的治疗方法,最初专注于严重的呼吸系统疾病。他们正在开发verekitug,这是目前临床开发中唯一已知的拮抗剂,靶向胸腺间质淋巴细胞生成素(“TSLP”)受体,TSLP是一种细胞因子,是临床验证的炎症反应驱动因素,位于影响各种免疫介导疾病的多个信号级联的上游。迄今为止的临床前和临床数据表明,verekitug对TSLP受体具有高度有效的抑制作用,这将转化为差异化的产品特征,包括改善临床结果、大幅延长给药间隔和治疗广泛患者的潜力。他们经验丰富的团队致力于最大限度地发挥verekitug的独特属性,以满足当今护理标准无法满足的患者的大量未满足需求。","exchange":"NASDAQ","name":"UpStream Bio Inc.","nameEN":"UpStream Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"UpStream Bio Inc.,UPB,UpStream Bio Inc.股票,UpStream Bio Inc.股票老虎,UpStream Bio Inc.股票老虎国际,UpStream Bio Inc.行情,UpStream Bio Inc.股票行情,UpStream Bio Inc.股价,UpStream Bio Inc.股市,UpStream Bio Inc.股票价格,UpStream Bio Inc.股票交易,UpStream Bio Inc.股票购买,UpStream Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"UpStream Bio Inc.(UPB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供UpStream Bio Inc.(UPB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}